Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer and the most common subtype of pediatric leukemia, the high toxicity, relapse and refractory disease of many patients require the development of novel therapeutic approaches. New therapeutic approaches such as targeted immunotherapy in combination with Hematopoietic Stem Cell Transplantation (HSCT) must be taken in count to revolutionize the management of numerous ALL subtypes, improve treatment outcomes and maintain low toxicity without losing the effectiveness of the treatment. We evaluated a novel therapeutic approach in Mexico, the outpatient administration of blinatumomab infusion in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).